Related references
Note: Only part of the references are listed.Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES
Melani Sooriyaarachchi et al.
DALTON TRANSACTIONS (2010)
Analytical methodologies for metallomics studies of antitumor Pt-containing drugs
Diego Esteban-Fernandez et al.
METALLOMICS (2010)
Platinum Drug Distribution in Cancer Cells and Tumors
Alice V. Klein et al.
CHEMICAL REVIEWS (2009)
Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting
Katherine S. Lovejoy et al.
DALTON TRANSACTIONS (2009)
Analysis of the plasma metalloproteome by SEC-ICP-AES: bridging proteomics and metabolomics
Shawn A. Manley et al.
EXPERT REVIEW OF PROTEOMICS (2009)
Simultaneous Cu-, Fe-, and Zn-specific detection of metalloproteins contained in rabbit plasma by size-exclusion chromatography-inductively coupled plasma atomic emission spectroscopy
Shawn A. Manley et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2009)
Polymeric Drug Delivery of Platinum-Based Anticancer Agents
Katherine J. Haxton et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Chemotherapy-associated renal dysfunction
Vaibhav Sahni et al.
NATURE REVIEWS NEPHROLOGY (2009)
Probing the interaction of arsenobetaine with blood plasma constituents in vitro: an SEC-ICP-AES study
Katie L. Pei et al.
METALLOMICS (2009)
The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry
Elke E. M. Brouwers et al.
ANTI-CANCER DRUGS (2008)
Atomic (HPLC-ICP-MS) and molecular mass spectrometry (ESI-Q-TOF) to study cis-platin interactions with serum proteins
Diego Esteban-Fernandez et al.
JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY (2008)
Distinct mechanisms for ctr1-mediated copper and cisplatin transport
Devis Sinani et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
A study of the interactions between carboplatin and blood plasma proteins using size exclusion chromatography coupled to inductively coupled plasma mass spectrometry
Ruimin Xie et al.
ANALYTICAL AND BIOANALYTICAL CHEMISTRY (2007)
Molecular mechanisms of resistance and toxicity associated with platinating agents
Cara A. Rabik et al.
CANCER TREATMENT REVIEWS (2007)
Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity
S van Zutphen et al.
COORDINATION CHEMISTRY REVIEWS (2005)
A mass spectrometric and molecular modelling study of cisplatin binding to transferrin
I Khalaila et al.
CHEMBIOCHEM (2005)
Cellular processing of platinum anticancer drugs
D Wang et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose
Y Li et al.
EUROPEAN JOURNAL OF CANCER (2004)
Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group
R Mandal et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2004)
Determination of drug binding sites to proteins by electrospray ionisation mass spectrometry: the interaction of cisplatin with transferrin
CS Allardyce et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2002)
The (ir)relevance of plasma protein binding of anticancer drugs
A Sparreboom et al.
NETHERLANDS JOURNAL OF MEDICINE (2001)
Share Paper
